CAR T-cell therapy offers substantial remission rates in trial
In a Phase III study, a CAR T-cell therapy more than tripled progression-free survival compared with standard care for multiple myeloma.
Source: europeanpharmaceuticalreview.com
Page 32 - Hematologic Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hematologic Malignancies Today - Breaking & Trending Today
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The FDA has approved Brukinsa (zanubrutinib) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: oncologynurseadvisor.com
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The FDA has approved Brukinsa (zanubrutinib) for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Source: empr.com
Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia
A head-to-head clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has found that zanubrutinib, a next-generation BTK inhibitor, was more effective at preventing disease progression and better tolerated than ibrutinib, the first-generation BTK inhibitor that is the current s
Source: pressreleasepoint.com
ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia
12.12.2022 - - Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML- No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax - ALX Oncology ... Seite 1
Source: wallstreet-online.de